Your browser doesn't support javascript.
loading
Benefits of and Barriers to Pharmacogenomics-Guided Treatment for Major Depressive Disorder.
Ahmed, Ahmed T; Weinshilboum, Richard; Frye, Mark A.
Affiliation
  • Ahmed AT; Department of Psychiatry and Psychology and Mayo Clinic Depression Center, Rochester, Minnesota, USA.
  • Weinshilboum R; Division of Clinical Pharmacology, Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
  • Frye MA; Department of Psychiatry and Psychology and Mayo Clinic Depression Center, Rochester, Minnesota, USA.
Clin Pharmacol Ther ; 103(5): 767-769, 2018 05.
Article in En | MEDLINE | ID: mdl-29388201
ABSTRACT
Antidepressants have reduced the symptom burden for many Major Depressive Disorder (MDD) patients, but drug-related side effects and treatment resistance continue to present major challenges. Pharmacogenomics represents one approach to enhance antidepressant efficacy and avoid adverse reactions, but concerns remain with regard to the overall "value equation," and several barriers must be overcome to achieve the full potential of MDD pharmacogenomics.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Depressive Disorder, Major / Antidepressive Agents Limits: Humans Language: En Journal: Clin Pharmacol Ther Year: 2018 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Depressive Disorder, Major / Antidepressive Agents Limits: Humans Language: En Journal: Clin Pharmacol Ther Year: 2018 Type: Article Affiliation country: United States